{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:13Z","timestamp":1786984333275,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.amjcard.2017.11.021","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T00:03:10Z","timestamp":1511913790000},"page":"509-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus"],"prefix":"10.1016","volume":"121","author":[{"given":"Brian W.","family":"Gilbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Sherard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Branstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.11.021_bib0010","first-page":"918","article-title":"Increasing prevalence of diagnosed diabetes\u2014United States and Puerto Rico, 1995\u20132010","volume":"61","author":"Centers for Disease and Prevention","year":"2012","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0015","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","article-title":"Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease","volume":"167","author":"Franco","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.298.7.765","article-title":"Diabetes and mortality following acute coronary syndromes","volume":"298","author":"Donahoe","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0025","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.11.021_bib0030","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc07-S004","article-title":"Standards of medical care in diabetes: 2007","volume":"30","author":"American Diabetes Association","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1520-765X(04)80002-6","article-title":"Inhibition of late (sustained\/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function","volume":"6","author":"Belardinelli","year":"2004","journal-title":"Eur Heart J"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.11.021_bib0040","first-page":"1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus","volume":"13","author":"American Association of Clinical Endocrinologists","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0045","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00392-014-0796-x","article-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","volume":"104","author":"Hammond","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.phrs.2011.06.018","article-title":"Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts","volume":"64","author":"Aldakkak","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0060","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1c and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases b-cell survival and improves glucose homeostasis in low-dose streptozotocin-induced diabetes in mice","volume":"337","author":"Ning","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0070","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2337\/db13-1562","article-title":"Blockade of Na channels in pancreatic cells has antidiabetic effects","volume":"63","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0075","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.amjcard.2015.08.002","article-title":"Comparative effectiveness of ranolazine versus traditional therapies in chronic stable angina pectoris and concomitant diabetes mellitus and impact on health care resource utilization and cardiac interventions","volume":"116","author":"Page","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.atherosclerosis.2012.10.051","article-title":"Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus","volume":"226","author":"Lamendola","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0085","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12629","article-title":"Effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin","volume":"18","author":"Pettus","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0090","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0095","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0100","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2017.11.021_bib0105","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2337\/dc16-S008","article-title":"Glycemic targets","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pharmthera.2011.11.003","article-title":"Role of ranolazine in angina, heart failure, arrhythmias, and diabetes","volume":"133","author":"Sossalla","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0115","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc09-1727","article-title":"The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis","volume":"33","author":"Sherifali","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects 13 with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.11.021_bib0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917318088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917318088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T11:36:03Z","timestamp":1660044963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917318088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0002914917318088"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.11.021","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}